Oral polio caused 47,500 non-polio acute flaccid paralysis (NPAFP) in India in 2011 researchers reported “…while India has been polio-free for a year, there has been a huge increase in non-polio acute flaccid paralysis (NPAFP).  In 2011, there were an extra 47,500 new cases of NPAFP.  Clinically indistinguishable from polio paralysis but twice as deadly, the incidence of NPAFP was directly proportional to doses of oral polio received.  Though this data was collected within the polio surveillance system, it was not investigated.  The principle of primum-non-nocere [First, do no harm] was violated.”  This was never on the evening news as are many other negative outcomes of vaccines.

Reference:  http://www.ncbi.nlm.nih.gov/pubmed/22591873

Jonas Salk, inventor of the Inactivated Polio Virus (IPV), testified before a Senate subcommittee that nearly all polio outbreaks since 1961 were caused by the oral polio vaccine. "Crib death" was so infrequent in the pre-vaccination era that it was not even mentioned in the statistics, but it started to climb in the 1950s with the spread of mass vaccination against diseases of childhood.

- Harris L. Coulter, PhD.

The truth about Polio

Dr. Bernard Greenberg, a biostatistics expert, was chairman of the Committee on Evaluation and Standards of the American Public Health Association during the 1950s.  He testified at a panel discussion that was used as evidence for the congressional hearings on polio vaccine in 1962.  During these hearings he elaborated on the problems associated with polio statistics and disputed claims for the vaccine's effectiveness.  He attributed the dramatic decline in polio cases to a change in reporting practices by physicians.  Fewer cases were identified as polio after the vaccination for very specific reasons. "Prior to 1954 any physician who reported paralytic poliomyelitis was doing his patient a service by way of subsidizing the cost of hospitalization and was being community-minded in reporting a communicable disease.  The criterion of diagnosis at that time in most health departments followed the World Health Organization

definition: "Spinal paralytic poliomyelitis: signs and symptoms of non-paralytic poliomyelitis with the addition of partial or complete paralysis of one or more muscle groups, detected on two examinations at least 24 hours apart."  Note that "two examinations at least 24 hours apart" was all that was required.  Laboratory confirmation and presence of residual paralysis was not required. In 1955 the criteria were changed to conform more closely to the definition used in the 1954 field trials: residual paralysis was determined 10 to 20 days after onset of illness and again 50 to 70 days after onset.... This change in definition meant that in 1955 we started reporting a new disease, namely, paralytic poliomyelitis with a longer-lasting paralysis.  Furthermore, diagnostic procedures have continued to be refined. Coxsackie virus infections and aseptic meningitis have been distinguished from paralytic poliomyelitis.  Prior to 1954 large numbers of

these cases undoubtedly were mislabeled as paralytic poliomyelitis.

Reference: From Intensive Immunization Programs, Hearings before the Committee on Interstate & Foreign Commerce, House of Representatives, 87th Congress, 2nd Session on H.R. 10541, Wash DC: Us Government Printing Office, 1962; p. 96-97

                                                                                                                                             Simian Virus 40 (SV40):A Cancer Causing Monkey Virus from FDA-Appoved Vaccines

                                                                                                                                             Between 1959 and 1960, Bernice Eddy, Ph.D., of the National Institute of Health (NIH) examined minced rhesus monkey kidney cells under a  microscope.  These were the cells of the same species of monkeys used to create and produce the oral polio vaccine. Dr. Eddy discovered that the cells would die without any apparent cause.  She then took suspensions of the cellular material from these kidney cell cultures and injected them into hamsters. Cancers grew in the hamsters.  Shortly thereafter, scientists at the pharmaceutical company Merck & Co. discovered what would later be determined to be the same virus identified by Eddy.  This virus was named Simian Virus 40 or SV40 because it was the 40th simian virus found in monkey kidney cells.

In 1960, Doctors Benjamin Sweet and Maurice Hilleman, the Merck scientists who named the virus SV40, published their findings:

The vacuolating virus was another name for SV40.

In 1962, Dr. Bernice Eddy published her findings in the journal produced by the Federation of American Societies for Experimental Biology. She wrote:

There is now an impressive list of oncogenic (cancer causing) viruses—the rabbit papilloma, polyoma, Rous sarcoma, the leukemia viruses . . . . It has been known for a number of years that monkeys harbor latent viruses . . . . The (SV40) virus was injected at once into 13 newborn hamsters and 10 newborn mice.  Subcutaneous neoplasms indistinguishable from those induced by the rhesus monkey kidney extracts developed in 11 of the 13 hamsters between 156 and 380 days.

Subsequent studies performed in the early 1960s demonstrated that SV40 caused brain tumors in animals and that SV40 could transform or turn cancerous normal human tissue in vitro.  A disturbing experiment performed during this era also suggested that SV40 could cause human cancers in man in vivo.  In 1964, Fred Jensen and his colleagues took tissue from patients who were terminally ill with cancer. They exposed the tissue to SV40 and then after it was transformed, they implanted the tissue back into the patient.  These implants grew into tumors in their human hosts.  This suggested the possibility that SV40 could cause cancers in man.

In July 2002, the National Academy of Science Institute of Medicine (IOM) Immunization Safety Committee convened a study into SV40 and cancer which culminated in a report published in October 2002.  According to the IOM report “SV40 Contamination of Polio Vaccine and Cancer”:

The committee concludes that the biological evidence is strong that SV40 is a transforming [i.e., cancer-causing] virus, . . . that the biological evidence is of moderate strength that SV40 exposure could lead to cancer in humans under natural conditions, [and] that the biological evidence is of moderate strength that SV40 exposure from the polio vaccine is related to SV40 infection in humans.

Reference:  http://www.sv40foundation.org/CPV-link.html

Me and mine chose to get vacccinated,we know about the risk if we do not!!!If you chose for you and your family not to, who is taking the bigger gamble you or me!!??

The Effectiveness of Vaccination against Influenza in Healthy, Working Adults

Kristin L. Nichol, M.D., M.P.H., April Lind, M.S., Karen L. Margolis, M.D., M.P.H., Maureen Murdoch, M.D., M.P.H., Rodney McFadden, M.D., Meri Hauge, R.N., Sanne Magnan, M.D., Ph.D., and Mari Drake, M.P.H.

N Engl J Med 1995; 333:889-893October 5, 1995DOI: 10.1056/NEJM199510053331401

Background

Although influenza causes substantial morbidity and mortality in all age groups, current recommendations emphasize annual immunization for people at high risk for complications of influenza. We conducted a double-blind, placebo-controlled trial of vaccination against influenza in healthy, working adults

Results

We enrolled a total of 849 subjects. Base-line characteristics were similar in the two groups. During the follow-up period, consisting of the 1994–1995 influenza season (December 1, 1994, through March 31, 1995), those who received the vaccine reported 25 percent fewer episodes of upper respiratory illness than those who received the placebo (105 vs. 140 episodes per 100 subjects, P<0.001), 43 percent fewer days of sick leave from work due to upper respiratory illness (70 vs. 122 days per 100 subjects, P = 0.001), and 44 percent fewer visits to physicians' offices for upper respiratory illnesses (31 vs. 55 visits per 100 subjects, P = 0.004). The cost savings were estimated to be $46.85 per person vaccinated.

http://www.nejm.org/doi/full/10.1056/NEJM199510053331401

Objectives

• To conduct population-based research on immunization safety questions
• To evaluate immunization safety hypotheses that arise from medical literature, passive surveillance systems, adjustments to immunization schedules, and introduction of new vaccines
• To guide national immunization policy decisions
• To partner with healthcare providers, public health officials, and others to ensure the public has the best available information regarding the risks and benefits of immunization.

Documents released through the Freedom of Information Act detail the transcript of a meeting held in June of 2000 between members of the CDC, the FDA, and representatives from the vaccine industry.

The exact cause of Guillain-Barre syndrome is unknown. In about 60 percent of cases, an infection affecting either the lungs or the digestive tract precedes the disorder. Recent surgery, immunization and pregnancy have also been associated with Guillain-Barre syndrome. But scientists don't know why such an infection can lead to Guillain-Barre syndrome for some people and not for others. Many cases appear to occur without any triggers.

In Guillain-Barre syndrome, your immune system — which usually attacks only foreign material and invading organisms — begins attacking the nerves that carry signals to your brain. In the most common form of Guillain-Barre syndrome in North America, the nerves' protective covering (myelin sheath) is damaged, and this interferes with the signaling process, causing weakness, numbness or paralysis.